The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study
Open accessAbstract
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While similar in distribution, the magnitude of the CBF response in depression patients was distinctly less than that in the study of healthy volunteers by Riba et al. [141].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“Parametric mapping of CBF changes indicated increases in some very small clusters (<50 voxels) localized to the left nucleus accumbens, right insula, and left cingulate cortex, which the authors felt to be regions activated by antidepressant treatments.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“the mean Hamilton depression rating scales declined from 25 to 15 in the three hours after administration, and remained around 10 during the following three weeks.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“These open label [22–24] and randomised control [21] trials have suggested that ayahuasca may produce rapid and significant reductions in depression symptoms in as little as 1 day.”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [23]
In the citing paper
“Several studies, including one RCT, have highlighted a similar rapid onset and sustained antidepressant effect after a single ingestion in patients diagnosed with treatment-resistant depression (3, 36).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [36]
In the citing paper
“Similarly, ayahuasca's anti-depressive potential has been demonstrated in pilot studies and replicated in a RCT on patients with treatment-resistant depression (33, 36, 63).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
In the citing paper
“For example, enhanced activation of the ACC and other prefrontal regions was observed in novice and experienced meditators (120–122), and as a result of ayahuasca administration (33, 63).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
Citations
Cites
Pizzagalli, D. A., Holmes, A. J., Dillon, D. G., Goetz, E. L., Birk, J. L., Bogdan, R., Dougherty, D. D., Iosifescu, D. V., Rauch, S. L., & Fava, M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081201 · Cited by 1,232
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
The subgenual anterior cingulate cortex in mood disorders
Drevets, W. C., Savitz, J., & Trimble, M. (2008) · CNS Spectrums · doi:10.1017/s1092852900013754 · Cited by 1,109
A meta‐analytic study of changes in brain activation in depression
Fitzgerald, P. B., Laird, A. R., Maller, J., & Daskalakis, Z. J. (2008) · Human Brain Mapping · doi:10.1002/hbm.20426 · Cited by 903
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Self-citationVollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Research works printed but not linked: 1
- Moreno, 1998, Hamilton (HAM-D) Montgomery Asberg (MADRS) depression rating scales., Rev Psiquiatr Clin, 25, 262
Cited by
Sorted by citations
Items 201–300 of 466
Rossi, G. N., Hallak, J. E. C., Bouso, J. C., & SANTOS, R. G. D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066650 · Cited by 26
Self-citationIsham, A., Elf, P., & Jackson, T. P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1051478 · Cited by 25
Zheng, Z.-H., Lin, X.-C., Lu, Y., Cao, S.-R., Liu, X.-K., Dong, L., Yang, F.-H., Zhang, Y.-B., Tu, J., Pan, B., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110208 · Cited by 25
Psychedelia: The interplay of music and psychedelics
Jerotic, K., Vuust, P., & Kringelbach, M. L. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15082 · Cited by 27
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Taylor, A. P., Mortari, M. R., & Caldas, E. D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00854-w · Cited by 23
da Silva, M. G., Daros, G. C., & de Bitencourt, R. M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113003 · Cited by 27
The use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 25
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodríguez, C. I., Kalin, N. H., & McDonald, W. M. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19104 · Cited by 28
Callon, C., Williams, M., & Lafrance, A. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211043300 · Cited by 21
SANTOS, R. G. D., Rocha, J. M., Rossi, G. N., Osório, F. D. L., Oña, G., Bouso, J. C., Silveira, G. D. O., Yonamine, M., Marchioni, C., Crevelin, E. J., et al. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2834 · Cited by 21
Self-citationScoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21
Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study
Dorsen, C. G., Palamar, J. J., & Shedlin, M. G. (2018) · Addiction Research & Theory · doi:10.1080/16066359.2018.1455187 · Cited by 23
Ayahuasca and the traveller: A scoping review of risks and possible benefits
Houle, S. K. D., Evans, D., Carter, C. A., & Schlagenhauf, P. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102206 · Cited by 20
Depression as a Disorder of Consciousness
Whiteley, C. M. K. (2021) · The British Journal for the Philosophy of Science · doi:10.1086/716838 · Cited by 21
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability
Rossi, G. N., Dias, I. C. D. S., Baker, G. B., Bouso, J. C., Dursun, S. M., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2054988 · Cited by 23
Self-citationA Systematic Review on the Therapeutic Effects of Ayahuasca
Gonçalves, J., Luís, Â., Gallardo, E., & Duarte, A. P. (2023) · Plants · doi:10.3390/plants12132573 · Cited by 27
James, E., Erritzøe, D., Benway, T. A., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B., Barba, T., Campbell, G., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1305796 · Cited by 20
Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review
White, E., Kennedy, T., Ruffell, S., Perkins, D., & Sarris, J. J. (2024) · International Journal of Toxicology · doi:10.1177/10915818241230916 · Cited by 21
Nogueira, M., Golbert, D. C. F., de Menezes, R. S. T., de Almeida, R. N., Coelho, N. L. G., Siroky, A. N., Lima, T. Z., Maia, H., Leão, K. E., & Leão, R. N. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02655-w · Cited by 22
A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers
Ables, J. L., Israel, L., Wood, O., Govindarajulu, U. S., Fremont, R. T., Banerjee, R., Liu, H., Cohen, J., Wang, P., Kumar, K., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241273772 · Cited by 20
A Physician’s Attempt to Self-Medicate Bipolar Depression with N,N-Dimethyltryptamine (DMT)
Brown, T., Shao, W., Ayub, S., Chong, D., & Cornelius, C. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1344898 · Cited by 20
Hallucinogens and Their Therapeutic Use: A Literature Review
Begola, M. J., & Schillerstrom, J. E. (2019) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000409 · Cited by 20
Adaptive mechanisms following antidepressant drugs: Focus on serotonin 5-HT2A receptors
Gawliński, D., Smaga, I., Zaniewska, M., Gawlińska, K., Faron‐Górecka, A., & Filip, M. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.05.012 · Cited by 19
Schenberg, E. E., & Gerber, K. (2022) · Transcultural Psychiatry · doi:10.1177/13634615211062962 · Cited by 21
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 22
The current state of ayahuasca research in animal models: A systematic review
Daldegan‐Bueno, D., Simionato, N. M., Favaro, V. M., & Maia, L. O. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110738 · Cited by 21
Perkins, D., Opaleye, E. S., Bouso, J. C., Tófoli, L. F., Sarris, J. J., Schubert, V., Ruffell, S., & Šimonová, H. (2023) · Psychoactives · doi:10.3390/psychoactives2040017 · Cited by 21
Solaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 22
Ahmadi, J., & Jahromi, M. S. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2017.1400063 · Cited by 19
Eckernäs, E., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12933 · Cited by 15
SANTOS, R. G. D., Enyart, S., Bouso, J. C., Parés, Ò., & Hallak, J. E. C. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.008 · Cited by 18
Self-citationSet and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Estric, C., Duron, T., Kabani, S., & López‐Castromán, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338214 · Cited by 18
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
Alves, C. L., Cury, R. G., Roster, K. I. O., Pineda, A. M., Rodrigues, F. A., Thielemann, C., & Ciba, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277257 · Cited by 17
Jager, J. E. D., Boesjes, R., Roelandt, G. H. J., Koliaki, I., Sommer, I. E., Schoevers, R. A., & Nuninga, J. O. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105796 · Cited by 18
Gomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 21
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 20
de Camargo, R. W., Joaquim, L. D. S., Machado, R. S., Ramos, S. D. S., da Rosa, L. R., Júnior, L. R. D. N., Mathias, K., Maximiano, L., Strickert, Y. R., Nord, R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04597-4 · Cited by 18
Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic
Horák, M., Hasíková, L., & Verter, N. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1511878 · Cited by 17
Natural Psychoplastogens As Antidepressant Agents
Benko, J., & Vranková, S. (2020) · Molecules · doi:10.3390/molecules25051172 · Cited by 17
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2288-z · Cited by 17
Self-citationCellular rules underlying psychedelic control of prefrontal pyramidal neuronsPreprint
Ekins, T. G., Brooks, I. A. W., Kailasa, S., Rybicki-Kler, C., Jedrasiak‐Cape, I., Donoho, E., Mashour, G. A., Rech, J. C., & Ahmed, O. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563334 · Cited by 19
Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation
Daneluz, D. M., Sohn, J. M. B., Silveira, G. D. O., Yonamine, M., & Stern, C. A. J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06217-2 · Cited by 17
Egger, K., Gudmundsen, F., Jessen, N. S., Baun, C., Poetzsch, S. N., Shalgunov, V., Herth, M. M., Quednow, B. B., Martin-Söelch, C., Dornbierer, D., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140656 · Cited by 19
Ayahuasca: what mental health professionals need to know
dos Santos, R. D., Bouso, J., & Hallak, J. (2017) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000130 · Cited by 12
Self-citationSanabria, E. (2021) · BioSocieties · doi:10.1057/s41292-020-00222-4 · Cited by 16
van Oorsouw, K. I. M., Uthaug, M. V., Mason, N. L., Broers, N. J., & Ramaekers, J. G. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00174 · Cited by 17
Ledwos, N., Rosenblat, J. D., Blumberger, D. M., Castle, D. J., McIntyre, R. S., Mulsant, B. H., & Husain, M. I. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001608 · Cited by 18
Moderators of ayahuasca’s biological antidepressant action
de Sousa, G. M., Tavares, V. D. D. O., Galvão, A. C. D. M., de Almeida, R. N., Palhano-Fontes, F., Soares, B. L., Freire, F. A. D. M., Nunes, E. A., Maia‐de‐Oliveira, J. P., Perkins, D., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1033816 · Cited by 17
Self-citationFalchi-Carvalho, M., Barros, H., Bolcont, R., Laborde, S., Wießner, I., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., et al. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0002 · Cited by 20
Ayahuasca: Pharmacology, Safety, and Therapeutic Effects
SANTOS, R. G. D., & Hallak, J. E. C. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009585330.005 · Cited by 20
Self-citationOña, G., & Bouso, J. C. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191212103330 · Cited by 18
Effectiveness of Psilocybin on Depression: A Qualitative Study
Alshaikhli, H., Al-Naggar, R. A., & Erlam, G. D. (2021) · Electronic Journal of General Medicine · doi:10.29333/ejgm/10862 · Cited by 21
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
Apud, I., Scuro, J., Carrera, I., & Oliveri, A. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2053004 · Cited by 14
Postpartum depression: A role for psychedelics?
Jairaj, C., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093793 · Cited by 16
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Spitalier, A., & Mendive, F. M. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.23-00005 · Cited by 14
Wong, S., Yu, A. Y., Fabiano, N., Finkelstein, O., Pasricha, A., Jones, B. D. M., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Husain, M. I. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251133 · Cited by 15
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001725 · Cited by 15
Lessons to be learned from early psychedelic therapy in Denmark
Erritzøe, D., & Richards, W. A. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1336252 · Cited by 14
Whole Organisms or Pure Compounds? Entourage Effect Versus Drug Specificity
Ribeiro, S. T. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-76720-8_8 · Cited by 14
Barnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
Brouns, E. J., Ekins, T. G., & Ahmed, O. J. (2025) · Psychedelics. · doi:10.61373/pp025r.0002 · Cited by 13
Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers
Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 14
Self-citationSanchez, T. A., Ramos, L. R., Araujo, F., Schenberg, E. E., Yonamine, M., Lobo, I., de Araújo, D. B., & Luna, L. E. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117430 · Cited by 14
Kuburi, S., Passa, A.-M. D., Tassone, V. K., Mahmood, R., Lalovic, A., Ladha, K. S., Dunlop, K., Rizvi, S. J., Demchenko, I., & Bhat, V. (2022) · Chronic Stress · doi:10.1177/24705470221115342 · Cited by 14
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Psychedelic medicines for mood disorders: current evidence and clinical considerations.
Sarris, J. J., Rubiano, D. P., Day, K., Coelho, N. L. G., & Perkins, D. (2022) · PubMed · doi:10.1097/yco.0000000000000759 · Cited by 12
Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior
Grilo, M. L. P. D. M., de Sousa, G. M., de Mendonça, L. A. C., Soares, B. L., de Sousa, M. B. C., Palhano-Fontes, F., de Araújo, D. B., Perkins, D., Hallak, J. E. C., & Coelho, N. L. G. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.901425 · Cited by 16
Self-citationPsychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001727 · Cited by 13
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 12
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
Olivier, B., & Olivier, J. D. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_3 · Cited by 12
A landscape analysis of psychedelic retreat organizations advertising online
Neitzke‐Spruill, L., Beit, C. S., Robinson, J. O., Singh, N., Kambala, S., Ramesh, R., & McGuire, A. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321648 · Cited by 12
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors
Ekins, T. G., Rybicki-Kler, C., Deng, T., Brooks, I. A. W., Jedrasiak‐Cape, I., Donoho, E., & Ahmed, O. J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03257-w · Cited by 13
Nižňanský, Ľ., Nižnanská, Ž., Kuruc, R., Szórádová, A., Šikuta, J., & Zummerová, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041147 · Cited by 13
Filho, L. A. M. D. S. D., Amariz, I. A. E., Nishimura, R. H. V., Massaranduba, A. B. R., Menezes, P. M. N., Damasceno, T. A., Brys, I., Rolim, L. A., Silva, F. S., & Ribeiro, L. A. D. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221104050 · Cited by 12
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“Similar reductions in depression symptoms have been described with ayahuasca, a brew containing DMT from the Psychotria viridis plant and monoamine oxidase inhibitors from the Banisteriopsis caapi vine (19-21).”
BackgroundChaves, C., SANTOS, R. G. D., Dursun, S. M., Tusconi, M., Carta, M. G., Brietzke, E. M., & Hallak, J. E. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1485337 · Cited by 11
Self-citationEcheverry, C., Pazos, M., Torres‐Pérez, M., & Prunell, G. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.039 · Cited by 12
Daldegan‐Bueno, D., Favaro, V. M., Morais, P. R., Sussulini, A., & Oliveira, M. G. M. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113878 · Cited by 11
Longo, M. S. C., Bienemann, B., Multedo, M., Negreiros, M. A., Schenberg, E. E., & Mograbi, D. C. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2112788 · Cited by 14
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 12
Campagnoli, A. P. S., Pereira, L. A. S., & Bueno, J. L. O. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209278 · Cited by 14
Recent Evidence on the Antidepressant Effects of Ayahuasca
Palhano-Fontes, F., Mota-Rolim, S. A., Soares, B. L., Coelho, N. L. G., Maia‐de‐Oliveira, J. P., & de Araújo, D. B. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_2 · Cited by 12
Self-citationTherapeutic potential of psychedelics: History, advancements, and unexplored frontiers
Maia, J. M., de Oliveira, B. S. A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110951 · Cited by 11
Lowe, M. X., Kettner, H., Jolly, D. R. P., Carhart-Harris, R. L., & Jackson, H. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1279887 · Cited by 14
Mueller, M. J., Aicher, H., Dornbierer, D., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I. A., Müller, J., Poetzsch, S. N., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf001 · Cited by 10
Lashgari, N., Khalaji, M., Rana, P., Badrabadi, F., Rahnama, M., Nasoori, H., Roudsari, N. M., Nia, M. M. K., & Shafaroodi, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05097-9 · Cited by 10
Classic psychedelics as therapeutics for psychiatric disorders
Nichols, C. D., & Hendricks, P. S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00049-9 · Cited by 11
Ayahuasca in the Czech Republic: Extended Version
Horák, M., & Verter, N. (2019) · doi:10.11118/978-80-7509-657-9 · Cited by 10
Rational Suicide in the Elderly
Balasubramaniam, M., & McCue, R. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6 · Cited by 10
Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay
Kummrow, F., Maselli, B. D. S., Lanaro, R., Costa, J. L., Umbuzeiro, G. D. A., & Linardi, A. (2018) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22263 · Cited by 11
Adverse Effects After Ayahuasca Administration in the Clinical Setting
Rocha, J. M., Rossi, G. N., Osório, F. L., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001536 · Cited by 10
Self-citationThe Resurgence of Hallucinogen Drugs in Clinical Research
Rivera-Garcia, M. T., & Cruz, S. L. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000108 · Cited by 12
Context is a Critical for Psychoactive Drug Effects
Greenway, K. T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01053-0 · Cited by 9
Existential feelings as a phenomenological framework for psychedelic therapy
Tijhuis, F. B., Coninx, S., & de Bruin, L. C. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2412195 · Cited by 10
Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans
SANTOS, R. G. D., Crippa, J. A. S., Osório, F. D. L., Rocha, J. M., Rossi, G. N., Marchioni, C., Queiroz, M. E. C., Silveira, G. D. O., Yonamine, M., & Hallak, J. E. C. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000973 · Cited by 9
Self-citationde Oliveira, R. C., Behrens, C. S. B., Nagamine-Pinheiro, N., Fagg, C. W., Silva, M. S. E., Martins-Silva, T., & Sonsin‐Oliveira, J. (2023) · Economic Botany · doi:10.1007/s12231-023-09567-w · Cited by 9
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Scholkmann, F., & Vollenweider, F. X. (2022) · Neurophotonics · doi:10.1117/1.nph.10.1.013506 · Cited by 9
Presa, M. H., da Rocha, M. J., Pires, C. S., Ledebuhr, K. N. B., da Costa, G. P., Alves, D. A. C., Bortolatto, C. F., & Brüning, C. A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00108 · Cited by 8
Metadata
- Authors
- Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Corresponding author
- Sanches, Rafael Faria
- Macedo, Ligia R.H.
- Crippa, José Alexandre S.
- Hallak, Jaime E.C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2016-02
- Volume
- 36
- Issue
- 1
- Pages
- 77-81
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2419844652
- Cited by
- 466
- References
- 26
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 63 · 2023: 55 · 2022: 68 · 2021: 59 · 2020: 39 · 2019: 28 · 2018: 41 · 2017: 31 · 2016: 14
- FWCI
- 35.96
- Type
- journal article
- Language
- en
- Open access
- green
- repositorio.ufrn.br
- Licence
- other-oa
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ayahuasca, recurrent depression, antidepressant effects, dimethyltryptamine, harmine, 5-HT2A receptor agonism, monoamine oxidase A inhibition, regional cerebral blood flow, nucleus accumbens, insula, dissociative states, adverse effects, single-dose administration
- MeSH terms
- Administration, Oral, Adult, Antidepressive Agents, Brain, Major Depressive Disorder, Female, Hallucinogens, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Time Factors, Tomography, Emission-Computed, Single-Photon, Treatment Outcome, Plant Preparations, Banisteriopsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
